Today: 28 January 2026
Subscribe
Browse Category

Pharmaceutical Industry News 21 January 2026 - 27 January 2026

Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

New York, Jan 27, 2026, 14:29 (EST) — Regular session Shares of Gilead Sciences climbed $2.46, or 1.8%, to $140.24 Tuesday afternoon, hitting a fresh 12-month peak at $141.69 earlier in the session. The stock’s steady climb is pulling momentum money back into big-cap biotech, as traders focus on research notes suggesting estimates are beatable and policy noise is calming…
27 January 2026
·····
AbbVie stock rises as insurers crater and the Fed week kicks off

AbbVie stock rises as insurers crater and the Fed week kicks off

New York, Jan 27, 2026, 14:28 EST — Regular session AbbVie Inc. shares climbed roughly 1.5% to $224.12 in Tuesday afternoon trading, having peaked earlier at $226.83. Johnson & Johnson also rose about 1.5%, and Pfizer was up around 2.6%. Meanwhile, Eli Lilly fell close to 1.2%. The move is crucial as the market attempts to sustain a rally ahead…
27 January 2026
·····
AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

New York, January 26, 2026, 14:50 (EST) — Regular session AbbVie Inc. shares edged up roughly 0.4% to hit $220.10 in afternoon trading on Monday, fluctuating between $217.15 and $221.48 earlier in the session. The stock’s modest shift is notable since it hits a key pressure point for the sector: earnings, guidance, and Washington risk are all converging now. Health-care…
26 January 2026
·····
GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+

GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+

London, Jan 26, 2026, 07:59 GMT — Premarket GSK (GSK.L) announced that the European Commission has greenlit its RSV vaccine Arexvy for adults 18 and older, expanding eligibility beyond those 60-plus and high-risk individuals aged 50 to 59. “This approval helps protect all adults aged 18 and older in Europe against RSV,” said Sanjay Gurunathan, GSK’s head of Vaccines and…
26 January 2026
···
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

New York, Jan 23, 2026, 19:39 EST — After-hours Gilead Sciences shares climbed 3.65%, closing at $135.93 on Friday. The stock gained momentum after fresh breast cancer data refocused attention on the company’s oncology efforts. (Yahoo Finance) Gilead announced that full Phase 3 data from the ASCENT-04/KEYNOTE-D19 trial have been published in the New England Journal of Medicine. The study…
24 January 2026
····
Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

New York, January 22, 2026, 17:37 EST — Trading after the bell. Eli Lilly and Company shares gained roughly 0.8% in after-hours Thursday, last seen at $1,087.38, up $8.81. During the session, the stock fluctuated between $1,072.46 and $1,095.15. Investors are once again focusing on a key concern for Lilly: the duration patients remain on its blockbuster weight-loss drugs and…
23 January 2026
····
Johnson & Johnson stock price today: JNJ ends higher, but talc case stays in focus after earnings

Johnson & Johnson stock price today: JNJ ends higher, but talc case stays in focus after earnings

New York, Jan 22, 2026, 17:46 EST — After-hours Johnson & Johnson shares ended Thursday roughly 0.3% higher at $218.49, after moving between $217 and $221.86 during the session. Trading volume hit around 13 million shares. The move was modest, but the backdrop is anything but. J&J’s initial glimpse at 2026 arrives amid mounting U.S. pressure on drug pricing and…
22 January 2026
·····
Johnson & Johnson stock price swings late as JNJ guidance beats views, but talc risk grabs traders again

Johnson & Johnson stock price swings late as JNJ guidance beats views, but talc risk grabs traders again

New York, January 21, 2026, 17:55 EST — After-hours Johnson & Johnson shares dipped 0.05% to $218.01 in after-hours trading Wednesday, swinging from a low of $209.20 to a high of $218.61. Investors balanced the company’s 2026 forecast with fresh scrutiny over talc-related lawsuits. The numbers are crucial as J&J aims to prove it can sustain growth despite mounting challenges.…
22 January 2026
·····
Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

New York, January 21, 2026, 17:20 EST — After-hours Eli Lilly’s stock jumped 3.6% on Wednesday, finishing at $1,078.52. The boost came after the company announced that the U.S. Food and Drug Administration awarded Breakthrough Therapy designation to its experimental ovarian cancer drug. (Stock Titan) The Breakthrough Therapy program aims to fast-track the development and review of drugs for serious…
21 January 2026
·····
RAPT stock hovers near $58 as GSK buyout puts tender offer clock in focus

RAPT stock hovers near $58 as GSK buyout puts tender offer clock in focus

New York, Jan 21, 2026, 12:09 EST — Regular session. RAPT Therapeutics (RAPT.O) held steady on Wednesday, trading around $57.60 midday on Nasdaq. The shares ticked up just 0.05% during the session. After Tuesday’s sharp reprice, the shares are trading more like a deal spread than a high-flying biotech stock. That matters because what’s next largely boils down to routine…
21 January 2026
·····
Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

New York, Jan 20, 2026, 20:41 EST — Market closed. Merck & Co’s stock ended Tuesday 0.57% higher, closing at $109.45, supported by long-term data on a personalized melanoma vaccine it’s working on with Moderna, which helped steady investor sentiment as the session wrapped up. (Finviz) The update is crucial as Merck aims to expand its growth story beyond Keytruda,…
21 January 2026
·······
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

NEW YORK, Jan 20, 2026, 18:51 EST — After-hours Rapt Therapeutics (NASDAQ: RAPT) surged roughly 64% to $57.57 in after-hours trading Tuesday following news that Britain’s GSK will acquire the U.S. biotech. GSK’s $58-a-share cash bid values the deal at about a 65% premium over Monday’s close. This is the first big move by CEO Luke Miels, who just took…
21 January 2026
·····
1 2 3 … 11

Stock Market Today

  • Molson Coors (TAP) Stock Shows Potential Undervaluation Amid Price Drop
    January 27, 2026, 10:56 PM EST. Molson Coors Beverage's stock closed at $48.46 after a recent 3.1% weekly decline and an 8.4% drop over the past year, underperforming peers. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by approximately 68%, estimating intrinsic value at $153.07 per share versus current price. The DCF model projects rising free cash flow from $1.08 billion to $1.33 billion by 2030. Molson Coors scores 5 out of 6 in Simply Wall St's valuation, indicating price weakness may not reflect true company worth amid evolving beverage market dynamics. Investors should weigh these valuation metrics alongside ongoing competitive challenges and shifting consumer preferences when considering the stock.
Go toTop